NASDAQ:GRPH Graphite Bio (GRPH) Stock Forecast, Price & News $2.97 +0.05 (+1.71%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.87▼$2.9750-Day Range$2.41▼$3.3852-Week Range$1.59▼$4.48Volume106,973 shsAverage Volume226,566 shsMarket Capitalization$172.56 millionP/E RatioN/ADividend YieldN/APrice Target$3.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Graphite Bio MarketRank™ ForecastAnalyst RatingHold1.89 Rating ScoreUpside/Downside12.2% Upside$3.33 Price TargetShort InterestHealthy2.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.05) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.74 out of 5 starsMedical Sector779th out of 983 stocksBiological Products, Except Diagnostic Industry128th out of 164 stocks 1.9 Analyst's Opinion Consensus RatingGraphite Bio has received a consensus rating of Hold. The company's average rating score is 1.89, and is based on no buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.33, Graphite Bio has a forecasted upside of 12.2% from its current price of $2.97.Amount of Analyst CoverageGraphite Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.77% of the float of Graphite Bio has been sold short.Short Interest Ratio / Days to CoverGraphite Bio has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldGraphite Bio does not currently pay a dividend.Dividend GrowthGraphite Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GRPH. Previous Next 1.8 News and Social Media Coverage News SentimentGraphite Bio has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Graphite Bio this week, compared to 1 article on an average week.Search Interest1 people have searched for GRPH on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Graphite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders38.45% of the stock of Graphite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.51% of the stock of Graphite Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Graphite Bio are expected to grow in the coming year, from ($1.05) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Graphite Bio is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Graphite Bio is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGraphite Bio has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Graphite Bio (NASDAQ:GRPH) StockGraphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More Receive GRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Graphite Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GRPH Stock News HeadlinesMay 31, 2023 | americanbankingnews.comGraphite Bio, Inc. (NASDAQ:GRPH) Receives Average Rating of "Reduce" from BrokeragesMay 21, 2023 | americanbankingnews.comCantor Fitzgerald Analysts Reduce Earnings Estimates for Graphite Bio, Inc. (NASDAQ:GRPH)June 2, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 15, 2023 | markets.businessinsider.comSVB Securities Sticks to Their Hold Rating for Graphite Bio (GRPH)May 15, 2023 | finance.yahoo.comGraphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22%May 10, 2023 | finance.yahoo.comShould You Buy Graphite Bio (GRPH) Ahead of Earnings?May 4, 2023 | americanbankingnews.comAnalysts Set Graphite Bio, Inc. (NASDAQ:GRPH) Price Target at $3.33April 21, 2023 | americanbankingnews.comReviewing Sangamo Therapeutics (NASDAQ:SGMO) & Graphite Bio (NASDAQ:GRPH)June 2, 2023 | Behind the Markets (Ad)U.S. Loses to China in Shocking WAR GAMES=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>April 9, 2023 | americanbankingnews.comGraphite Bio, Inc. (NASDAQ:GRPH) Receives $3.33 Average PT from AnalystsApril 1, 2023 | finanznachrichten.deNorthern Graphite Corporation: Northern Graphite Increases Size of Mousseau West ProjectMarch 25, 2023 | finance.yahoo.comWe're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn RateMarch 24, 2023 | americanbankingnews.comRoyal Bank of Canada Trims Graphite Bio (NASDAQ:GRPH) Target Price to $3.00March 23, 2023 | americanbankingnews.comFY2023 EPS Estimates for Graphite Bio, Inc. (NASDAQ:GRPH) Lifted by AnalystMarch 23, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Graphite Bio, Inc. (NASDAQ:GRPH) Raised by SVB LeerinkMarch 22, 2023 | americanbankingnews.comGraphite Bio (NASDAQ:GRPH) Issues Earnings ResultsMarch 22, 2023 | americanbankingnews.comGraphite Bio (NASDAQ:GRPH) Posts Earnings Results, Beats Estimates By $0.05 EPSMarch 21, 2023 | markets.businessinsider.comBTIG Sticks to Its Hold Rating for Graphite Bio (GRPH)March 20, 2023 | finance.yahoo.comGraphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial ResultsFebruary 24, 2023 | marketwatch.comGraphite Bio to Reduce Workforce by 50%, Explores Strategic AlternativesFebruary 24, 2023 | benzinga.comGraphite Bio shares are trading higher after the company announced a process to explore strategic alternatives.February 23, 2023 | finance.yahoo.comSickle-cell gene therapy developer stops program, cuts half of staffFebruary 23, 2023 | msn.comGraphite Bio adds 10%, most in eight months even as downgrades pile upFebruary 22, 2023 | finance.yahoo.comGraphite Bio Announces Process to Explore Strategic Alternatives and Corporate RestructuringJanuary 25, 2023 | markets.businessinsider.comExpert Ratings for Graphite BioJanuary 10, 2023 | finance.yahoo.comDown -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a TurnaroundJanuary 9, 2023 | msn.comLooking Into Graphite Bio's Recent Short InterestSee More Headlines GRPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRPH Company Calendar Last Earnings5/11/2023Today6/02/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GRPH CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployees69Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.33 High Stock Price Forecast$7.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+12.2%Consensus RatingHold Rating Score (0-4)1.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,050,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.47% Return on Assets-29.25% Debt Debt-to-Equity RatioN/A Current Ratio18.85 Quick Ratio18.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.75 per share Price / Book0.63Miscellaneous Outstanding Shares58,100,000Free Float35,762,000Market Cap$172.56 million OptionableNot Optionable Beta0.09 Key ExecutivesDr. Joshua Lehrer-Graiwer FACC (Age 48)M.D., Pres, CEO & Director Comp: $724.58kDr. Matthew Porteus M.D. (Age 57)Ph.D., Academic Founder & Director Comp: $90.77kDr. Maria Grazia Roncarolo M.D. (Age 68)Ph.D., Academic Founder & Chair of Scientific Advisory Board Comp: $70kMr. Philip P. Gutry (Age 49)Chief Bus. Officer Comp: $541.33kDr. Daniel Dever Ph.D.Co-Founder & Head of Discovery ResearchMs. Alethia Rene Young (Age 43)Chief Financial Officer Dr. Christine Garrett P.M.P. (Age 51)Ph.D., Chief of Staff & Sr. VP of Operations Mr. Jerry Cacia (Age 55)Chief Technical Officer Dr. Jane Grogan Ph.D. (Age 54)Chief Scientific Officer Stephanie YaoVP of Communications & Investor RelationsMore ExecutivesKey CompetitorsGritstone bioNASDAQ:GRTSAtara BiotherapeuticsNASDAQ:ATRAC4 TherapeuticsNASDAQ:CCCCVaxartNASDAQ:VXRTAdaptimmune TherapeuticsNASDAQ:ADAPView All CompetitorsInstitutional OwnershipBoard of Trustees of The Leland Stanford Junior UniversityBought 243,784 shares on 5/16/2023Ownership: 1.208%Geode Capital Management LLCBought 4,844 shares on 5/16/2023Ownership: 0.425%Susquehanna International Group LLPBought 117,300 shares on 5/16/2023Ownership: 0.000%Jane Street Group LLCBought 55,675 shares on 5/16/2023Ownership: 0.096%Squarepoint Ops LLCBought 14,113 shares on 5/16/2023Ownership: 0.024%View All Institutional Transactions GRPH Stock - Frequently Asked Questions Should I buy or sell Graphite Bio stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Graphite Bio in the last twelve months. There are currently 1 sell rating and 8 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRPH, but not buy additional shares or sell existing shares. View GRPH analyst ratings or view top-rated stocks. What is Graphite Bio's stock price forecast for 2023? 9 brokerages have issued twelve-month price targets for Graphite Bio's shares. Their GRPH share price forecasts range from $2.00 to $7.00. On average, they predict the company's share price to reach $3.33 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price. View analysts price targets for GRPH or view top-rated stocks among Wall Street analysts. How have GRPH shares performed in 2023? Graphite Bio's stock was trading at $3.32 at the beginning of 2023. Since then, GRPH stock has decreased by 10.5% and is now trading at $2.97. View the best growth stocks for 2023 here. When is Graphite Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our GRPH earnings forecast. How were Graphite Bio's earnings last quarter? Graphite Bio, Inc. (NASDAQ:GRPH) released its earnings results on Thursday, May, 11th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.08. When did Graphite Bio IPO? (GRPH) raised $224 million in an IPO on Friday, June 25th 2021. The company issued 14,000,000 shares at a price of $15.00-$17.00 per share. What is Graphite Bio's stock symbol? Graphite Bio trades on the NASDAQ under the ticker symbol "GRPH." Who are Graphite Bio's major shareholders? Graphite Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (14.67%), K2 Principal Fund L.P. (1.67%), Prosight Management LP (1.51%), Board of Trustees of The Leland Stanford Junior University (1.21%), BlackRock Inc. (0.87%) and Federated Hermes Inc. (0.70%). Insiders that own company stock include Biocapital LP Samsara and Phil Gutry. View institutional ownership trends. How do I buy shares of Graphite Bio? Shares of GRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Graphite Bio's stock price today? One share of GRPH stock can currently be purchased for approximately $2.97. How much money does Graphite Bio make? Graphite Bio (NASDAQ:GRPH) has a market capitalization of $172.56 million. The company earns $-101,050,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. How can I contact Graphite Bio? The official website for the company is www.graphitebio.com. The company can be reached via phone at 650-484-0886 or via email at ir@graphitebio.com. This page (NASDAQ:GRPH) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graphite Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.